Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss
The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the world. Now, the pharma giant wants to reinvest its success with weight-loss meds into tackling some of the world’s toughest health challenges.
From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
This weight loss drug reduces heart failure risk
A groundbreaking study shows how Zepbound, a popular weight loss medication, could become a key treatment for heart failure patients while reducing death rates.
New weight loss drugs aim to promote muscle growth
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors say they may also need to demonstrate
Zepbound for Weight Loss: What to Know About This Weight Loss Drug
For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and
Fat, not muscle: drugmakers in race for next weight-loss breakthrough
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
This antibody prevents muscle loss in weight loss drugs
Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope for safer treatment options.
Eli Lilly obesity drug trial participants losing ‘too much weight,’ STAT reports
In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements,
Lilly's next obesity drug serves up dramatic weight loss -- and side effects - report
Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say that while they have seen incredible weight loss, it has also come with its share of notable side effects.
Weight-loss drug Zepbound helped drive Ireland to $76 billion in goods exports to the U.S. last year—a bittersweet reminder of the challenges ahead
Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.
KOMU2d
FDA approves first drug to aid sleep apnea; drug also results in weight loss
The FDA approved a new drug called Zepbound, which activates GLP-1 to help with obstructive sleep apnea, while also resulting ...
Attorney General Wilson calls for FDA to act on counterfeit weight loss, diabetes drugs
South Carolina Attorney General Alan Wilson announced he is leading 37 states on a territory bipartisan coalition requesting ...
Some Ozempic users are developing serious eye issues that lead to blindness
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...
The Physicians Really Are Healing Themselves, With Ozempic
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...